![]() |
市場調查報告書
商品編碼
1936611
創傷性腦損傷評估市場機會、成長要素、產業趨勢分析及預測(2026年至2035年)Traumatic Brain Injuries Assessment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035 |
||||||
全球創傷性腦損傷評估市場預計到 2025 年將達到 23 億美元,預計到 2035 年將達到 40 億美元,年複合成長率為 5.2%。

市場擴張的促進因素包括頭部創傷病例的增加、運動和軍事相關腦外傷病例的增多,以及神經影像和診斷技術的不斷進步。腦外傷評估涉及全面的臨床、認知和神經系統評估,以確定腦損傷的嚴重程度、功能影響和整體預後。神經系統測試、行為評估、影像技術和生物標記分析被整合在一起,以促進快速診斷、治療方案製定和預後判斷。此外,CT、MRI、EEG和基於生物標記的診斷技術的創新使得能夠更快、更準確地檢測出以前往往被忽視的輕度和中度腦外傷,從而進一步推動了市場成長。人工智慧驅動的分析、客觀的診斷工具和基於血液的篩檢解決方案的日益普及也在推動產業轉型。
| 市場覆蓋範圍 | |
|---|---|
| 開始年份 | 2025 |
| 預測期 | 2026-2035 |
| 起始值 | 23億美元 |
| 預測金額 | 40億美元 |
| 複合年成長率 | 5.2% |
由於其快速、經濟高效且非侵入性的評估能力,預計到2025年,篩檢設備市場佔有率將達到80.1%。這些設備對於在急診和臨床環境中早期發現和優先處理疑似腦損傷至關重要,因此得到了廣泛應用。
2025年,醫院領域佔據57.9%的市場佔有率,預計2026年至2035年間將達到24億美元。醫院是頭部創傷患者的主要治療中心,大量患者湧入使得先進的評估工具必不可少。道路交通事故和老齡化相關損傷的增加是導致住院人數上升的主要因素,進一步凸顯了對高效腦外傷評估解決方案的需求。
預計到2025年,美國創傷性腦損傷評估市場規模將達到8.816億美元。北美市場需求主要受意外事故、跌倒及其他原因導致的頭部損傷所驅動,這使得急救醫療服務提供者對快速且準確的診斷工具提出了更高的要求。醫院和急診對先進神經診斷解決方案的依賴,也持續推動美國市場的成長。
The Global Traumatic Brain Injuries Assessment Market was valued at USD 2.3 billion in 2025 and is estimated to grow at a CAGR of 5.2% to reach USD 4 billion by 2035.

Market expansion is driven by the increasing prevalence of head injuries, the rising number of sports-related and military-associated TBIs, and ongoing advancements in neuroimaging and diagnostic technologies. Traumatic brain injury assessment involves a comprehensive clinical, cognitive, and neurological evaluation to determine the severity, functional impact, and overall outcome of brain injuries. It incorporates neurological tests, behavioral assessments, imaging techniques, and biomarker analysis to facilitate prompt diagnosis, treatment planning, and prognosis. The market is further fueled by innovations in CT, MRI, EEG, and biomarker-based diagnostics, enabling faster and more accurate detection of mild and moderate TBIs, which were often overlooked previously. Growing adoption of AI-driven analytics, objective diagnostic tools, and blood-based screening solutions is also reshaping the industry.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $2.3 Billion |
| Forecast Value | $4 Billion |
| CAGR | 5.2% |
The screening devices segment held an 80.1% share in 2025, due to their rapid, cost-effective, and non-invasive assessment capabilities. These devices are essential for early detection and prioritization of suspected brain injuries in emergency and point-of-care settings, driving their widespread adoption.
The hospitals segment held a 57.9% share in 2025, expected to reach USD 2.4 billion during 2026-2035. Hospitals remain the primary care centers for head injury patients, with high patient inflow demanding advanced assessment tools. Rising road traffic incidents and age-related injuries are key factors contributing to increased hospital admissions, reinforcing the need for efficient TBI evaluation solutions.
U.S. Traumatic Brain Injuries Assessment Market was valued at USD 881.6 million in 2025. North America's demand is largely fueled by head injuries stemming from accidents, falls, and other causes, creating significant pressure on emergency care providers to adopt rapid and accurate diagnostic tools. The reliance on advanced neurodiagnostic solutions in hospitals and emergency units continues to drive the U.S. market forward.
Key players in the Global Traumatic Brain Injury Assessment Market include Philips, BrainScope, INTEGRA, RAUMEDIC, Fujifilm, Natus Medical, GE Healthcare, BIOMERIEUX, Oculogica, NIHON KOHDEN, InfraScan, SIEMENS Healthineers, COMPUMEDICS, and ZOLL Medical. To strengthen their presence, companies are pursuing strategies such as launching advanced diagnostic tools with faster turnaround times, integrating AI and machine learning into imaging platforms, and developing non-invasive biomarker-based tests. Many firms are expanding geographically to access high-growth regions and forming partnerships with hospitals, research institutions, and emergency care providers. Investment in marketing campaigns, training programs for healthcare professionals, and after-sales support ensures broader adoption and improved clinical outcomes.